Monitoring step counts to assess physical activity in glioma patients undergoing radiation therapy
Feasibility of Monitoring Step Count as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Patients Undergoing Radiation Therapy
This study is testing whether tracking step counts can help glioma patients undergoing radiation therapy understand how their physical activity affects their mood and energy levels.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT04186832 on ClinicalTrials.gov |
What this trial studies
This trial evaluates the feasibility of using step count monitoring as a measure of physical activity in patients newly diagnosed with glioma who are receiving radiation therapy at MD Anderson Cancer Center. Participants are randomized into two groups, one using a pedometer and the other a FitBit, to track their physical activity over a six-week period. The study aims to assess the impact of physical activity on cognitive function, fatigue, anxiety, and depression. Follow-up assessments will occur at three and six months post-radiation therapy to evaluate long-term effects.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with glioma who are about to start radiation therapy and meet specific performance and technology access criteria.
Not a fit: Patients with cognitive or major sensory deficits that hinder assessment completion may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the quality of life and symptom management for glioma patients undergoing treatment.
How similar studies have performed: Other studies have shown promise in using physical activity monitoring to improve patient outcomes, suggesting this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with a glioma and going to receive at least 4 weeks of RT at MDACC at the Texas Medical Center campus with at least 20 fractions * Karnofsky performance status (KPS) of 70 or above * Wearable activity tracker (WAT) - naive * Able to read and speak English * Able to provide informed consent * Access to a smartphone * Access to Wi-Fi Exclusion Criteria: * Cognitive and/or major sensory deficits that would impede the completion of assessment instruments as deemed by the clinical team
Where this trial is running
Houston, Texas
- M D Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Shiao-Pei S Weathers — M.D. Anderson Cancer Center
- Study coordinator: Shiao-Pei S Weathers
- Email: sweathers@mdanderson.org
- Phone: 713-792-2883
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.